What is Express Diagnostics Int'l?
Express Diagnostics Int'l, operating under the umbrella of CareHealth America Corp., is a key player in the drug testing solutions sector. The company specializes in a comprehensive suite of innovative drug testing products, including urine and saliva testing, alcohol testing, and fentanyl harm reduction initiatives. Leveraging cutting-edge research and domestic manufacturing capabilities, Express Diagnostics Int'l provides private labeling and contract manufacturing services. This strategic focus allows them to empower distribution partners with reliable and advanced drug testing solutions, aiming to deliver a competitive edge in the market.
How much funding has Express Diagnostics Int'l raised?
Express Diagnostics Int'l has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Express Diagnostics Int'l?
The substantial capital infusion, particularly the recent strategic investment, signals Express Diagnostics Int'l's intent to accelerate its growth trajectory. This funding is likely to be allocated towards expanding its product development pipeline, enhancing manufacturing capacity, and broadening its market reach. As a company in a large-scale, late-stage funding phase, Express Diagnostics Int'l is expected to focus on solidifying its market leadership and potentially exploring strategic partnerships or acquisitions to further its mission in providing advanced drug testing solutions.
See full Express Diagnostics Int'l company page
